Stifel lowered the firm’s price target on Definitive Healthcare (DH) to $5 from $6 and keeps a Buy rating on the shares. While “encouraged” by management’s actions to reaccelerate growth and improve profitability, the firm acknowledges that the stock’s valuation reflects the absence of near-term catalysts as the company’s turnaround continues.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DH:
- Definitive Healthcare price target lowered to $3 from $4 at Baird
- Definitive Healthcare Corp. Reports Q3 2025 Results
- Definitive Healthcare sees Q4 adjusted EPS 5c-6c, consensus 6c
- Definitive Healthcare raises FY25 adjusted EPS view to 23c-24c from 22c-23c
- Definitive Healthcare reports Q3 adjusted EPS 7c, consensus 5c